A comprehensive evaluation of the human Tg32 and Tg276 FcRn transgenic mouse and non-human primate models for predicting antibody pharmacokinetics in human
Monika Gajewska, Michael Kiffe, Claudio Calonder, Volker Engelhardt, Carla Pou i Miralbell, Elena Gonzalo-Gil, Gregory Christianson, Nijaguna Bethur, Adriano Flora · 2026
Read A comprehensive evaluation of the human Tg32 and Tg276 FcRn transgenic mouse and non-human primate models for predicting antibody pharmacokinetics in human by Monika Gajewska, Michael Kiffe, Claudio Calonder, Volker Engelhardt, Carla Pou i Miralbell, Elena Gonzalo-Gil, Gregory Christianson, Nijaguna Bethur, Adriano Flora (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13166230.txt.
Description
Gajewska and eight co-authors evaluate animal models used to predict how long antibodies stay in the human body, in a paper published in two thousand twenty-six. The key player is a receptor called FcRn, which rescues antibodies from breakdown and extends their life.
The team compared two mouse strains engineered with the human receptor against monkeys, using a large pool of published and in-house data. With the right scaling rules, which differ for half-life-extended antibodies, both mouse models predicted human behavior about as well as monkeys did. They also tested a version of one strain with a weakened immune system to avoid reactions against the drug. The results support replacing some monkey studies with mice.
Catalog record
| CREATOR | Monika Gajewska, Michael Kiffe, Claudio Calonder, Volker Engelhardt, Carla Pou i Miralbell, Elena Gonzalo-Gil, Gregory Christianson, Nijaguna Bethur, Adriano Flora |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 68 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |